Matching articles for "anemia"
Issue 1712 · September 30, 2024
Imetelstat (Rytelo) for Myelodysplastic Syndromes (online only)

The FDA has approved imetelstat ( Rytelo – Geron), a first-in-class telomerase inhibitor, for treatment of low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults with transfusion-dependent…

Med Lett Drugs Ther. 2024 Sep 30; 66(1712):e169-70 doi:10.58347/tml.2024.1712d
The FDA has approved imetelstat ( Rytelo – Geron), a first-in-class telomerase inhibitor, for treatment of low- to intermediate-1 risk myelodysplastic syndromes (MDS) in adults with transfusion-dependent anemia requiring 4 or more red blood cell (RBC) units over 8 weeks who have not responded to, are no longer responding to, or are ineligible for erythropoiesis-stimulating agents (ESAs).
Issue 1696 · February 19, 2024
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease

The FDA has approved daprodustat ( Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have…

Med Lett Drugs Ther. 2024 Feb 19; 66(1696):25-7 doi:10.58347/tml.2024.1696a
The FDA has approved daprodustat ( Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months. It is the first HIF-PHI and the first oral drug to be approved in the US for this indication.
Issue 1431 · December 9, 2013
Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia

The FDA has approved ferric carboxymaltose ( Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate or have…

Med Lett Drugs Ther. 2013 Dec 9; 55(1431):99-100
The FDA has approved ferric carboxymaltose ( Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate or have had an unsatisfactory response to oral iron and in those who have non-dialysis-dependent chronic kidney disease (CKD). It is the sixth IV iron product approved in the US.
Issue 1392 · June 11, 2012
Peginesatide (Omontys) for Anemia in Chronic Kidney Disease

The FDA has approved the erythropoiesis-stimulating agent (ESA) peginesatide ( Omontys – Affymax/Takeda), a synthetic peptide analog of erythropoietin, for treatment of anemia in patients with chronic kidney…

Med Lett Drugs Ther. 2012 Jun 11; 54(1392):45-6
The FDA has approved the erythropoiesis-stimulating agent (ESA) peginesatide ( Omontys – Affymax/Takeda), a synthetic peptide analog of erythropoietin, for treatment of anemia in patients with chronic kidney disease (CKD) who are on dialysis. Peginesatide is the third ESA to become available in the US.Overuse of the other two, which have broader indications, has been a concern.
Issue 1336 · April 19, 2010 Free
Correction: Ferumoxytol (Feraheme)

In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23) , the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1…

Med Lett Drugs Ther. 2010 Apr 19; 52(1336):32
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23) , the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Issue 1334 · March 22, 2010
Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation

Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease.…

Med Lett Drugs Ther. 2010 Mar 22; 52(1334):23-13
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in chronic kidney disease and may be associated with decreased absorption from the gastrointestinal tract, limiting the usefulness of oral iron replacement. IV iron replacement can lower the dose requirement for erythropoiesis-stimulating drugs, particularly in patients on dialysis
Issue 1270 · September 24, 2007
Eculizumab (Soliris) for Paroxysmal Nocturnal Hemoglobinuria

Eculizumab ( Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized…

Med Lett Drugs Ther. 2007 Sep 24; 49(1270):79-80
Eculizumab ( Soliris - Alexion) has been approved by the FDA for reduction of hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare form of hemolytic anemia. A recombinant humanized monoclonal antibody, eculizumab is the first drug to be marketed for this indication.
Issue 1260 · May 7, 2007
Erythropoietin Safety Concerns

The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based…

Med Lett Drugs Ther. 2007 May 7; 49(1260):37-9
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
Issue 1233 · April 24, 2006
Deferasirox (Exjade): A New Iron Chelator

Deferasirox ( Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions…

Med Lett Drugs Ther. 2006 Apr 24; 48(1233):35-6
Deferasirox ( Exjade - Novartis), an oral chelating agent, recently received accelerated approval from the FDA as an orphan drug for oral treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients >2 years old. Deferasirox is a tridentate (2 molecules of deferasirox bind to one atom of iron) chelating agent with high affinity for iron. It has much lower affinity for zinc and copper.
Issue 1232 · April 10, 2006
Lenalidomide (Revlimid) for Anemia of Myelodysplastic Syndrome

Lenalidomide ( Revlimid - Celgene), a thalidomide analog, has been approved by the FDA for treatment of patients with transfusion-dependent anemia due to myelodysplastic syndrome (MDS) associated with a 5q…

Med Lett Drugs Ther. 2006 Apr 10; 48(1232):31-2
Lenalidomide ( Revlimid - Celgene), a thalidomide analog, has been approved by the FDA for treatment of patients with transfusion-dependent anemia due to myelodysplastic syndrome (MDS) associated with a 5q deletion cytogenetic abnormality and a low or low-intermediate risk of mortality and progression to leukemia (based on the International Prognostic Scoring System).
Issue 1144 · November 25, 2002
Hemolysis From Ceftriaxone

Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a…

Med Lett Drugs Ther. 2002 Nov 25; 44(1144):100-1
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin) , one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209).
Issue 1104 · May 14, 2001
Erythropoietin (Procrit; Epogen) Revisited

Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA…

Med Lett Drugs Ther. 2001 May 14; 43(1104):40-1
Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA for treatment of anemia due to chronic renal failure, cancer chemotherapy or HIV treatment, and before elective non-cardiac surgery. It is also used illicitly by competitive athletes to increase their endurance.
Issue 801 · September 22, 1989
Erythropoietin For Anemia

Production of erythropoietin, a glycoprotein hormone secreted mainly by the kidney, is often low in patients with chronic renal failure (JW Eschbach, Kidney Int, 35:134, 1989). The US Food and Drug…

Med Lett Drugs Ther. 1989 Sep 22; 31(801):85-6
Production of erythropoietin, a glycoprotein hormone secreted mainly by the kidney, is often low in patients with chronic renal failure (JW Eschbach, Kidney Int, 35:134, 1989). The US Food and Drug Administration recently approved marketing of epoetin alfa ( Epogen - Amgen), a recombinant human erythropoietin, for treatment of anemia in such patients. Epoetin is commercially available in Europe as Eprex (Ortho), and Eprex is available from Ortho in the USA on an investigational basis for treatment of anemia related to AIDS. Epogen and Eprex are chemically identical.